Scientists track experimental cancer drug through healthy Volunteers' bodies
NCT ID NCT05879991
Summary
This early-stage study aimed to understand how the body absorbs, processes, and eliminates an experimental cancer drug called BI 1810631 (zongertinib). Researchers gave the drug to 15 healthy male volunteers in two different forms—as a liquid and as a pill—and tracked how much of it entered the bloodstream and how it left the body. The goal was to gather basic information about the drug's behavior to help design future studies in cancer patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON
Groningen, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.